All In Biotech

Drug Trial Radar · NCT03985878

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients With Duchenne Muscular Dystrophy Who Have Completed Study 4658-102

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

15

Actual

Start

Jun 26, 2019

Primary completion

Aug 31, 2022

Study completion Aug 31, 2022

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • EteplirsenDrug

    Eteplirsen IV infusion once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 162 weeks
  2. Number of Participants Experiencing Death Due to Adverse EventsTime frame: Up to 162 weeks
  3. Number of Participants Experiencing Adverse Events of Special Interest (AESIs)Time frame: Up to 162 weeks

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • UZ-Gent

    Ghent, Belgium

  • Hopital Trousseau, Bâtiment lemariey

    Paris, France

  • Fondazione Policlinico Universitario Agostino Gemelli, UOC Neuropsichiatria Infantile

    Rome, Italy

  • UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.